The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 869 Weight Management articles
Discover Retatrutide, a groundbreaking peptide with triple-receptor activity, poised to redefine metabolic health and weight management strategies. Learn about its science, potential, and what it means for the future of wellness.
Researchers at the University of Pennsylvania utilized artificial intelligence to analyze hundreds of thousands of Reddit posts, uncovering patient-reported side effects of GLP-1 medications that traditional clinical trials often overlook.
New data from D&D Pharmatech's Phase 2 trial for zabopegdutide, a GLP-1/glucagon dual receptor agonist, reveals promising results for patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. This development positions zabopegdutide as a potential contender in a growing market.
Honey, once a simple pantry staple, is now sought after as a natural wellness tool. While it remains a form of sugar, emerging research suggests its unique composition—rich in antioxidants and oligosaccharides—offers distinct benefits over refined sweeteners, potentially aiding in weight control and gut health.
The landscape of weight loss treatments is rapidly changing with the introduction of oral GLP-1 medications. This article delves into early adoption trends, comparing the initial uptake of Eli Lilly's oral semaglutide (Foundao) against Novo Nordisk's oral semaglutide (Wegovy's pill), and what these patterns signify for patients and physicians.
The unprecedented demand for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound is triggering a significant global expansion in peptide manufacturing. Learn how key players are investing billions to meet the surging need for these life-changing therapies.
Many assume BMI is the sole determinant for Mounjaro prescriptions, but the reality is far more nuanced. This article explores the comprehensive health criteria healthcare providers use to ensure safe and effective treatment.
The competition between Eli Lilly and Novo Nordisk is reshaping obesity treatment. Learn the clinical differences between Mounjaro and Wegovy, and why international market dynamics matter for patient access.
The European Medicines Agency has recommended approval for oral Wegovy, marking a significant shift in obesity treatment. Explore the implications for patients, efficacy data, and future access.
